NovaBay Pharmaceuticals Inc (NBY)
0.0773
0.00 (0.00%)
USD |
NYAM |
Apr 25, 16:00
0.0773
0.00 (0.00%)
After-Hours: 20:00
NovaBay Pharmaceuticals Research and Development Expense (Annual): 0.068M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.068M |
| December 31, 2022 | 0.174M |
| December 31, 2021 | 0.044M |
| December 31, 2020 | 0.285M |
| December 31, 2019 | 0.184M |
| December 31, 2018 | 0.259M |
| December 31, 2017 | 0.41M |
| December 31, 2016 | 1.371M |
| December 31, 2015 | 5.728M |
| December 31, 2014 | 9.483M |
| December 31, 2013 | 12.46M |
| Date | Value |
|---|---|
| December 31, 2012 | 9.275M |
| December 31, 2011 | 9.911M |
| December 31, 2010 | 8.616M |
| December 31, 2009 | 7.337M |
| December 31, 2008 | 9.595M |
| December 31, 2007 | 7.421M |
| December 31, 2006 | 4.087M |
| December 31, 2005 | 1.952M |
| December 31, 2004 | |
| December 31, 2003 | 0.27M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.044M
Minimum
2021
0.285M
Maximum
2020
0.151M
Average
0.174M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Eyenovia Inc | 12.98M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |